» Articles » PMID: 28477420

The Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans

Abstract

Sclerosteosis is a rare autosomal recessive bone disorder marked by hyperostosis of the skull and tubular bones. Initially, we and others reported that sclerosteosis was caused by loss-of-function mutations in SOST, encoding sclerostin. More recently, we identified disease-causing mutations in LRP4, a binding partner of sclerostin, in three sclerosteosis patients. Upon binding to sclerostin, LRP4 can inhibit the canonical WNT signaling that is known to be an important pathway in the regulation of bone formation. To further investigate the role of LRP4 in the bone formation process, we generated an Lrp4 mutated sclerosteosis mouse model by introducing the p.Arg1170Gln mutation in the mouse genome. Extensive analysis of the bone phenotype of the Lrp4R1170Q/R1170Q knock-in (KI) mouse showed the presence of increased trabecular and cortical bone mass as a consequence of increased bone formation by the osteoblasts. In addition, three-point bending analysis also showed that the increased bone mass results in increased bone strength. In contrast to the human sclerosteosis phenotype, we could not observe syndactyly in the forelimbs or hindlimbs of the Lrp4 KI animals. Finally, we could not detect any significant changes in the bone formation and resorption markers in the serum of the mutant mice. However, the serum sclerostin levels were strongly increased and the level of sclerostin in the tibia was decreased in Lrp4R1170Q/R1170Q mice, confirming the role of LRP4 as an anchor for sclerostin in bone. In conclusion, the Lrp4R1170Q/R1170Q mouse is a good model for the human sclerosteosis phenotype caused by mutations in LRP4 and can be used in the future for further investigation of the mechanism whereby LRP4 regulates bone formation. © 2017 American Society for Bone and Mineral Research.

Citing Articles

Mapping the sclerostin-LRP4 binding interface identifies critical interaction hotspots in loops 1 and 3 of sclerostin.

Katchkovsky S, Meiri R, Lacham-Hartman S, Orenstein Y, Levaot N, Papo N FEBS Lett. 2024; 599(3):316-329.

PMID: 39443289 PMC: 11808424. DOI: 10.1002/1873-3468.15033.


An Additional Lrp4 High Bone Mass Mutation Mitigates the Sost-Knockout Phenotype in Mice by Increasing Bone Remodeling.

Hendrickx G, Boudin E, Mateiu L, Yorgan T, Steenackers E, Kneissel M Calcif Tissue Int. 2023; 114(2):171-181.

PMID: 38051321 DOI: 10.1007/s00223-023-01158-0.


Genetic determinants of syndactyly: perspectives on pathogenesis and diagnosis.

Cassim A, Hettiarachchi D, Dissanayake V Orphanet J Rare Dis. 2022; 17(1):198.

PMID: 35549993 PMC: 9097448. DOI: 10.1186/s13023-022-02339-0.


Competitive blocking of LRP4-sclerostin binding interface strongly promotes bone anabolic functions.

Katchkovsky S, Chatterjee B, Abramovitch-Dahan C, Papo N, Levaot N Cell Mol Life Sci. 2022; 79(2):113.

PMID: 35099616 PMC: 11073160. DOI: 10.1007/s00018-022-04127-2.


Wnt Pathway Extracellular Components and Their Essential Roles in Bone Homeostasis.

Martinez-Gil N, Ugartondo N, Grinberg D, Balcells S Genes (Basel). 2022; 13(1).

PMID: 35052478 PMC: 8775112. DOI: 10.3390/genes13010138.